Innovative drugs continue to surge! Huabao Fund Hong Kong Stock Connect Innovative Drug ETF (520880) rapidly rises 2.46%! China Biologic Products new drug receives clinical approval, intraday surge reaches 8%

NightAirdropper · 2026-03-17T05:28:49+00:00

As of March 17, 2026, the Hong Kong Stock Connect Innovative Drug ETF (520880) rose 2.05% to 0.498 yuan, with a turnover rate of 11.56%. The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index tracked by this ETF performed well, with individual stocks such as Sansure Biotech rising significantly, and the latest fund size reaching 2.29 billion yuan.

NightAirdropper

2026-03-17 05:28:49

Abstract generation in progress

As of March 17, 2026, 10:29 AM, the Hong Kong Stock Connect Innovative Drug ETF (520880) rose by 2.05%, with a latest price of 0.498 yuan and a turnover rate of 11.56%.

The Hong Kong Stock Connect Innovative Drug ETF (520880) closely tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index. Among the index’s top holdings, Sihuan Pharmaceutical increased by 7.19%, Kelun Botech Biotech-B rose by 3.94%, and CSPC Pharmaceutical Group gained 3.88%. The index aims to reflect the performance of Hong Kong-listed companies that are tradable via the Hong Kong Stock Connect and are involved in the research, development, and production of innovative drugs. Base date: December 31, 2020. Base point: 3000.

Data shows that the latest size of the Hong Kong Stock Connect Innovative Drug ETF (520880) reached 2.29 billion yuan, with the latest shares outstanding at 4.7 billion shares.

Hong Kong Stock Connect Innovative Drug ETF (520880), over-the-counter connection (025220.OF, 025221.OF)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.